How To Choose the Right Valuation Framework in Digital Health

For digital health businesses, enterprise value is rarely explained by earnings alone. While EBITDA remains a useful indicator of operating performance, it does not fully capture durability, transferability, or risk‑adjusted sustainability. This gap exists because intangible assets create value in fundamentally different ways. Some drive economic performance directly, while others enable, protect, or condition it. As a result, valuation framework selection is not merely a technical exercise; it is a judgment about how value is actually created, sustained, and exposed to risk within the business. The appropriateness of any methodology is ultimately determined not by convention, but by alignment with underlying economics.

Where Digital Health Valuations Go Wrong

Valuation outcomes are often understood only after they are challenged—by auditors, regulators, transaction counterparties, or in litigation. At that point, the issue is rarely mathematical. Breakdowns typically reflect misjudged risk, misidentified assets, or assumptions that do not hold up under scrutiny. In digital health, these failures are rarely methodological in isolation; they arise because the assets and risks driving value are highly interdependent, difficult to isolate, and easily misclassified.

From a CFO perspective, the function of valuation is not price setting but risk identification and defensibility. Valuation conclusions which cannot be supported under scrutiny tend to fail regardless of analytical sophistication. Understanding where valuations go wrong allows finance leaders to anticipate issues before they surface in audits, transactions, or regulatory review.

Interdependence and the Risk of Double Counting

Few digital health assets generate economic benefit independently. Performance is typically the result of multiple elements working together. A proprietary dataset may have little standalone value without the algorithm trained on it; an algorithm cannot generate economic returns unless it is embedded into clinical workflows; workflow adoption depends on outcomes evidence; outcomes influence payor traction. While this interdependence enables performance, it also increases valuation risk.

For a CFO and an audit committee, the primary concern is double counting. When assets are evaluated in isolation without regard to how they interact, economic benefit can be inadvertently attributed multiple times. Defensible valuation requires clearly distinguishing between assets which are the primary drivers of economic benefit and assets that are contributory or enabling. When that bifurcation is unclear, valuation conclusions become difficult to support under review.

Workforce Dependence vs. Transferable Assets

A recurring source of breakdown is the misclassification of workforce‑driven capability as a transferable intangible asset. Early‑stage and growth‑stage businesses frequently derive value from specialized expertise, relationships, and execution that reside in individuals rather than systems. While these capabilities are often operationally critical, they do not automatically meet the criteria for separable or transferable assets. From a CFO perspective, this creates two risks:

Until these capabilities are embedded into validated datasets, standardized processes, or scalable platforms, they typically function as contributory assets rather than standalone intangibles.

Regulatory and Clinical Risk Premiums

Digital health valuations require risk adjustment beyond that observed in traditional technology sectors. Regulatory approvals, clinical validation, data governance requirements, and reimbursement uncertainty affect both the timing and probability of cash flow realization. Breakdowns occur when these risks are acknowledged qualitatively but not reflected quantitatively. Common red flags include:

A defensible valuation incorporates these factors explicitly (e.g., through discount rates, milestone‑based ramps, or probability weighting) rather than relying on optimistic base assumptions.

The Limits of Market Comparables

While market-based valuation approaches appeal to boards because of their simple and objective appearance, they are often misleading. The digital health sector spans virtual care, diagnostics, monitoring devices, digital therapeutics, patient engagement tools, and AI-enabled clinical decision support. Each of these domains has its own reimbursement pathways, regulatory classifications, and evidence requirements. Reliance on broad SaaS or “health tech” multiples can anchor expectations to benchmarks that do not withstand external review. In practice, market data functions best as a triangulation point rather than a primary valuation anchor.

MSO‑PC Structures and Fair Market Value Exposure

In MSO‑PC structures, valuation defensibility becomes a compliance issue as much as a financial one. Regulators closely evaluate whether management fees reflect fair market value for services actually provided. Common failure points include:

Timing Risk and Value Realization

Many digital health assets generate value only after extended timelines. Clinical studies, payor adoption, and workflow integration are inherently multi‑year processes. Valuations that assume compressed timelines or immediate scalability often mischaracterize economic reality. From a finance perspective, timing risk is frequently underweighted. Valuations that survive scrutiny tend to reflect these frictions explicitly rather than smoothing them away.

Choosing the Right Framework

The same factors that cause valuations to break down—asset interdependence, risk misclassification, and timing assumptions—also determine which valuation frameworks are appropriate. CFOs are not choosing between “correct” methodologies; they are selecting between approaches that answer different valuation questions. The objective is not methodological purity but alignment between the framework applied and the economic role the asset plays within the business.

When Income Approaches Make Sense

Income‑based methods are most appropriate where an asset directly drives economic performance. These approaches model how future cash flows emerge and persist but require a clear understanding of the role the asset plays within the broader operating structure. The relevant question is whether value should be measured as the asset’s contribution within the business or through an alternative economic lens.

When Other Valuation Approaches Make Sense

Not all intangible assets generate revenue directly. In digital health, some of the most critical assets instead enable the business to operate in the first place. Regulatory compliance and milestone-driven uncertainty often function as gatekeepers that determine when, how, and whether economic returns can be realized. In these situations, forcing an income-based model can obscure risk. Cost-based and scenario-based frameworks are often better suited to capturing these dynamics.

A Practical Takeaway: Use Method Triangulation

Digital health valuation rarely fails because of arithmetic. It fails when risk is understated, assets are misclassified, or assumptions cannot be defended under scrutiny. Used proactively, valuation frameworks surface weaknesses before they become audit findings, or transactional disputes.

No single valuation method captures the full economic realities of digital health, and no single failure mode explains every breakdown. Defensible conclusions typically emerge from method triangulation:

For CFOs, valuation is most effective when it aligns analytical conclusions with operational reality. Used consistently, it becomes a tool for managing risk and guiding decision‑making—not simply a mechanism for assigning value.